Gammagard to prevent infections in multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests if adding Gammagard (a type of antibody therapy) to your multiple myeloma treatment with Tecvayli can help prevent serious infections. You may qualify if you recently started Tecvayli and are still responding to it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have multiple myeloma and have started Tecvayli within the last 8 weeks.
- Plan to continue Tecvayli for at least the next 12 months.
- Be 18 years or older.
- Not have a serious infection or more than one serious infection in the last 3 months.
- Not have taken immunoglobulin products (like IVIG) in the last 16 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests two antibody medicines (teclistamab or talquetamab) given as outpatient injections, to treat multiple myeloma. It also tests preventing and treating side effects with supportive medicines, aiming to improve disease control in people who have already tried other myeloma treatments.
This Phase 2 study tests a study treatment in adults with multiple myeloma that needs treatment. It may help by trying to improve disease control after you’ve had (or are scheduled to have) standard therapy like chemotherapy and stem cell transplant for some people.
This Phase 2 trial studies how well teclistamab works when used in combination for people age 65 and older with multiple myeloma. It aims to see whether this treatment can control the cancer safely in older patients who may not do high-dose chemotherapy or stem cell transplant.
This trial tests a combination of two drugs—teclistamab (an immunotherapy) and mezigdomide (a targeted pill)—for people with multiple myeloma that has come back or not responded to previous treatments. The goal is to see if this new combination can help when other options have stopped working.
This trial tests two drugs (talquetamab and teclistamab) to see if they can eliminate remaining cancer cells in newly diagnosed myeloma patients who have already had a stem cell transplant. It may be an option if you have minimal residual disease (MRD) and a good response to initial treatment.
This study tests how well teclistamab works for people with multiple myeloma that has come back or not responded to at least three prior treatments. You may be eligible if you are starting teclistamab as part of your regular care.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.